MedTrace Logo

Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

NCT01041586 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-02-23

No results posted yet for this study

Summary

To assess the safety and efficacy of BTVA for the treatment of patients with heterogeneous upper lobe emphysema.

Conditions

Interventions

DEVICE

BTVA System

Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction

Sponsors & Collaborators

  • Uptake Medical Corp

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01041586 on ClinicalTrials.gov